Please login to the form below

Not currently logged in
Email:
Password:

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

Executive chairman Bob Hugin has decided to retire from Celgene after 19 years of service and will step down from the board of directors effective 5 February.

Hugin initially joined Celgene as its chief financial officer and then subsequently became chief operating officer and chief executive officer.

His successor will be Celgene’s current chief executive officer Mark Alles, who will remain as CEO along side his new position as the chairman of the board of directors.

Alles has been with Celgene since 2004, holding roles such as chief operational officer and executive vice president, global head of haematology and oncology.

Michael Casey, Celgene’s lead independent director, said: “Mark is a tremendous leader and the best person to guide Celgene into its next phase of significant growth.

“Through his strategic leadership as CEO, Celgene has advanced and expanded its portfolio of potentially life-changing medicines.”

6th February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics